World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
50534
World Ranking
6433
National Ranking
3423

Overview

Joel M. Kremer is affiliated with Albany Medical Center Hospital in the United States. Their research is primarily situated within the field of Medicine, with a strong focus on Rheumatology, Genetics, Pathology and Forensic Medicine, Hematology, and Immunology. Over the course of their career, they have contributed to various subfields and topics reflecting a broad involvement in medical research.

The scientist's recent scholarly work includes significant publications such as:

  • 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (2021) in Arthritis Care & Research
  • 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (2021) in Arthritis & Rheumatology
  • Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement (2020) in Annals of the Rheumatic Diseases
  • Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data (2020) in Annals of the Rheumatic Diseases
  • Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry (2021) in ACR Open Rheumatology

The main topics Joel M. Kremer has worked on include:

  • Rheumatoid Arthritis Research and Therapies
  • Systemic Lupus Erythematosus Research
  • Chronic Lymphocytic Leukemia Research
  • Autoimmune and Inflammatory Disorders Research
  • Lymphoma Diagnosis and Treatment
  • Biosimilars and Bioanalytical Methods
  • Monoclonal and Polyclonal Antibodies Research

Frequent coauthors collaborating with Kremer include:

  • Dimitrios A. Pappas
  • George Reed
  • Jeffrey R. Curtis
  • Taylor Blachley
  • Kelechi Emeanuru

The venues where Joel M. Kremer often publishes are:

  • Annals of the Rheumatic Diseases
  • Rheumatology and Therapy
  • Arthritis Care & Research
  • Arthritis & Rheumatology
  • ACR Open Rheumatology

Joel M. Kremer's body of work demonstrates a focused engagement with autoimmunity and inflammatory disorders, particularly through clinical trials, safety studies of pharmaceuticals, and consensus guidelines within rheumatology. Their collaborative network includes multiple researchers active in related medical and therapeutic domains, contributing to peer-reviewed journals frequently accessed by specialists in these fields.

Best Publications

  • A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

    Michael E. Weinblatt;Joel M. Kremer;Arthur D. Bankhurst;Ken J. Bulpitt

  • Genetics of rheumatoid arthritis contributes to biology and drug discovery

    Yukinori Okada;Yukinori Okada;Di Wu;Di Wu;Di Wu;Gosia Trynka;Gosia Trynka;Towfique Raj;Towfique Raj

  • 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

    Jasvinder A. Singh;Daniel E. Furst;Aseem Bharat;Jeffrey R. Curtis

  • Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

    Mark C Genovese;Jean-Claude Becker;Michael Schiff;Michael Luggen

  • Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.

    Joel M Kremer;Rene Westhovens;Marc Leon;Eduardo Di Giorgio

  • 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

    Liana Fraenkel;Joan M Bathon;Bryant R England;E William St Clair

  • Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

    Roy Fleischmann;Joel Kremer;John Cush;Hendrik Schulze-Koops

  • Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

    Joel M. Kremer;Harry K. Genant;Larry W. Moreland;Anthony S. Russell

  • IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

    P Emery;E Keystone;H P Tony;A Cantagrel

  • Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

    Stanley Cohen;Eric Hurd;John Cush;Michael Schiff

  • Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

    J M Kremer;G S Alarcón;R W Lightfoot;R F Willkens

  • Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects.

    Joel M. Kremer;David A. Lawrence;William Jubiz;Ralph Digiacomo

  • The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo

    Joel M. Kremer;Bradley J. Bloom;Ferdinand C. Breedveld;John H. Coombs

  • Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study.

    Joel M. Kremer;William Jubiz;Ann Michalek;Richard I. Rynes

  • Baricitinib in Patients with Refractory Rheumatoid Arthritis

    Mark C. Genovese;Joel Kremer;Omid Zamani;Charles Ludivico

  • Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept - Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial

    Joel J.M. Kremer;Maxime Dougados;Paul Emery;Patrick Durez

  • Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

    Désirée van der Heijde;Yoshiya Tanaka;Roy Fleischmann;Edward Keystone

  • Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate: Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year

    Joel M. Kremer;Ricardo Blanco;Marek Brzosko;Ruben Burgos-Vargas

  • Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

    Joel M. Kremer;Mark C. Genovese;Grant W. Cannon;Jacques R. Caldwell

  • Fish-Oil Fatty Acid Supplementation in Active Rheumatoid Arthritis

    Joel M. Kremer;William Jubiz;Ann Michalek;Richard I. Rynes

Frequent Co-Authors

George W. Reed
George W. Reed University of Massachusetts Chan Medical School
Jeffrey R. Curtis
Jeffrey R. Curtis University of Alabama at Birmingham
Mark C. Genovese
Mark C. Genovese Stanford University
Michael E. Weinblatt
Michael E. Weinblatt Brigham and Women's Hospital
Paul Emery
Paul Emery University of Leeds
Daniel H. Solomon
Daniel H. Solomon Brigham and Women's Hospital
Roy Fleischmann
Roy Fleischmann The University of Texas Southwestern Medical Center
Daniel E. Furst
Daniel E. Furst University of California, Los Angeles
Maxime Dougados
Maxime Dougados Hôpital Cochin
Robert M. Plenge
Robert M. Plenge Bristol Myers Squibb

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA isn’t limited to pursuing a traditional MD. There are many alternative online degrees and career possibilities in the healthcare field, catering to different educational backgrounds and career goals.

For those already holding an RN license, pursuing the cheapest rn to bsn online programs offers a practical and cost-effective path to advance your nursing career. These programs combine affordability with quality and flexibility, meeting the needs of working professionals.

If you're a non-nurse seeking a rapid transition into advanced practice roles, consider exploring direct entry np programs for non nurses online. These innovative options accelerate your pathway to becoming a nurse practitioner, even if your undergraduate degree isn’t in nursing.

Entry barriers can also be a concern. To broaden your opportunities, research whats the easiest nursing program to get into? so you can find accessible programs that match your academic profile and support your aspirations.

Beyond nursing, roles in healthcare administration and support are in high demand. Consider enrolling in online medical coding classes with financial aid to quickly gain valuable technical skills that open doors to remote and in-person healthcare settings.

Best Scientists Citing Joel M. Kremer

Trending Scientists